← Leaderboards
Houjian Cai
University Of Georgia
$3,852,418
Attributed
$5,146,467
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $785.4K · FY2013–24$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,146,467 · 4
By mechanism
U01$2,588,098 · 1
R01$1,736,925 · 1
R21$821,444 · 2
Top collaborators
- Lianchun Wang6 shared
Most similar at University Of Georgia
Same institution · by research overlap
- Lianchun Wang$10,893,566
- Ryan Joseph Weiss$2,040,003
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoProteinsProstateMalignant NeoplasmsTumorigenesisSignal TransductionMalignant Neoplasm Of ProstateAffectTumor ProgressionTumorCell MembraneMediatingSrc-Family KinasesMyristoylationN-MyristoyltransferaseAndrogen ReceptorPreventModificationIn VitroGeneticEpithelial CellsInhibitor/AntagonistCancer Patient
Grant awards (19)
Extracellular vesicles encapsulating CRISPR machinery for treatment of SARS-CoV-2 infection$184,222
R21 · FY2024 · AI · contact PI
Heparan Sulfate in Prostate Cancer$374,688
U01 · FY2023 · CA
Extracellular vesicles encapsulating CRISPR machinery for treatment of SARS-CoV-2 infection$221,972
R21 · FY2023 · AI · contact PI
Blocking TMPRSS2 expression for prevention of SARS-CoV-2 infection$188,750
R21 · FY2023 · AI · contact PI
Heparan Sulfate in Prostate Cancer$509,930
U01 · FY2022 · CA
Blocking TMPRSS2 expression for prevention of SARS-CoV-2 infection$226,500
R21 · FY2021 · AI · contact PI
Heparan Sulfate in Prostate Cancer$1
U01 · FY2021 · CA
Heparan Sulfate in Prostate Cancer$539,856
U01 · FY2020 · CA
Heparan Sulfate in Prostate Cancer$561,653
U01 · FY2019 · CA
Heparan Sulfate in Prostate Cancer$601,970
U01 · FY2018 · CA
Targeting myristoylation of Src family kinases for inhibition of prostate tumorig$311,250
R01 · FY2017 · CA · contact PI
Targeting myristoylation of Src family kinases for inhibition of prostate tumorig$311,250
R01 · FY2016 · CA · contact PI
Targeting myristoylation of Src family kinases for inhibition of prostate tumorig$48,525
R01 · FY2016 · CA · contact PI
Targeting myristoylation of Src family kinases for inhibition of prostate tumorig$48,525
R01 · FY2016 · CA · contact PI
Targeting myristoylation of Src family kinases for inhibition of prostate tumorig$311,250
R01 · FY2015 · CA · contact PI
Targeting myristoylation of Src family kinases for inhibition of prostate tumorigenesis$48,525
R01 · FY2015 · CA · contact PI
targeting myristoylation of Src family kinases for inhibition of prostate tumorig$48,525
R01 · FY2015 · CA · contact PI
Targeting myristoylation of Src family kinases for inhibition of prostate tumorig$299,900
R01 · FY2014 · CA · contact PI
Targeting myristoylation of Src family kinases for inhibition of prostate tumorig$309,175
R01 · FY2013 · CA · contact PI